Cancer News

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer (12/14/2017)

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and joint pain is a well documented concern of women undergoing AI therapy for the treatment and prevention of …

Continue reading "Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer"

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer (12/12/2017)

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer …

Continue reading "Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer"

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer (12/12/2017)

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for Keytruda, according to data presented at the 2017 San Antonio Breast Cancer Symposium. About HER2-Positive Breast Cancer About one in five …

Continue reading "Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer"

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer (11/01/2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive …

Continue reading "Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer"

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer (10/30/2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), …

Continue reading "Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer"

Radius Health Receives FDA Fast Track Designation for Elacestrant (10/26/2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies to …

Continue reading "Radius Health Receives FDA Fast Track Designation for Elacestrant"

Immunotherapy Active Against Triple-Negative Breast Cancer (10/12/2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), …

Continue reading "Immunotherapy Active Against Triple-Negative Breast Cancer"

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10/10/2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly …

Continue reading "LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations"

FDA approves new treatment for certain advanced or metastatic breast cancers (10/05/2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine …

Continue reading "FDA approves new treatment for certain advanced or metastatic breast cancers"

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (09/13/2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, …

Continue reading "Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths"